Table 8.
Primary and Secondary Efficacy Variables in Severe COVID-19 Patients
| Efficacy Variable | All patients (n=371) | MP 40 mg/d (n = 243) | DEX 5 mg/d(n = 128) | P-value | ||
|---|---|---|---|---|---|---|
| Primary outcomes | ||||||
| 30-day mortality, n (%) | 41(11.1%) | 28(10.4%) | 13(10.3%) | 0.746 | ||
| Exacerbation, n (%) | 127(34.2%) | 85(34.7%) | 42(33.3%) | 0.794 | ||
| Length of hospital Days, Mean(SD)/Median(IQR) days | 14.14(7.928)/12(8) | 13.43(8.21)/12(7) | 15.53(7.17)/14(10) | 0.001 | ||
| Secondary outcomes | ||||||
| Demand for NIPPV /IMV, n (%) | 52(14%) | 37(15.1%) | 15(11.9%) | 0.401 | ||
| The need for GC regimen escalation, n (%) | 43(11.6%) | 23(9.4%) | 20(15.9%) | 0.065 | ||
| Duration of GC treatment, Mean(SD)/Median(IQR) days | 8.8(4.75)/8(6) | 8.42(4.41)/8(5) | 9.54(5.304)/8(6) | 0.104 | ||
| Complications | ||||||
| Hyperglycemia, n (%) | 135(36.4%) | 94(38.4%) | 41(32.5%) | 0.269 | ||
| Fungal infection, n (%) | 52(14%) | 37(15.1%) | 15(11.9%) | 0.401 | ||
Note: Bold font indicates statistically significant values (p < 0.05).
Abbreviations: NIPPV, Non-invasive positive pressure ventilation; IMV, Invasive mechanical ventilation; SD, Standard Deviation; IQR, Interquartile distance.